Healthcare related spending accounted for more than 18% of the US GDP in 2018, roughly $3.65 trillion, and that number is on the rise. New science and technology, an aging populace, and a changing regulatory environment are combining to present incredible growth opportunities for small and middle-market companies in medical products and services – driving dynamic M&A activity.   

Accelerating competitive pressure and access to significant amounts of capital have led to an increase in specialization, partnering, and outsourcing rather than vertical integration—making deals in this sector more complicated and creating greater emphasis on a more expansive and detailed due diligence process.

Many investment banking and advisory firms specialize in subsectors of the Medical Technology & Services industry, but Dunn Rush & Co. brings key insights to the M&A process for privately held, family-owned middle-market companies that our competitors don’t. Our partners and managing directors have gone through exactly what you’re going through now—as CEOs, CTOs, and CFOs of middle-market companies in the Medical Technology & Services sector. We know what questions to ask, pitfalls to avoid, and how to identify the critical savings and synergies that need to be communicated effectively to buyers in order to achieve the maximum value and optimal outcome for you and your company.


  • Analytical Tools
  • Clinical Research Organizations
  • Diagnostics
  • Healthcare Information Technology
  • Healthcare Services
  • Home Healthcare Services
  • Imaging
  • Lab Consumables
  • Lab Services
  • Medical Devices
  • Wellness Devices


What Clients are Saying About Dunn Rush

Want to find out more? Get in touch.